

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

Department of the Treasury
Internal Revenue Service

▶ The organization may have to use a copy of this return to satisfy state reporting requirements.

A For the 2005 calendar year, or tax year beginning 10/01, 2005, and ending 09/30/2006

<p>B Check if applicable:</p> <p><input type="checkbox"/> Address change</p> <p><input type="checkbox"/> Name change</p> <p><input type="checkbox"/> Initial return</p> <p><input type="checkbox"/> Final return</p> <p><input type="checkbox"/> Amended return</p> <p><input type="checkbox"/> Application pending</p>	<p>Please use IRS label or print or type. See Specific Instructions.</p>	<p>C Name of organization <u>THE FOUNDATION FOR AIDS RESEARCH</u> (<u>DBA AMFAR, AIDS RESEARCH FOUNDATION</u>)</p> <p>Number and street (or P.O. box if mail is not delivered to street address) Room/suite <u>120 WALL STREET</u></p> <p><u>13TH FLOOR</u></p> <p>City or town, state or country, and ZIP + 4 <u>NEW YORK, NY 10005-3908</u></p>	<p>D Employer identification number <u>13-3163817</u></p> <p>E Telephone number <u>(212) 806-1600</u></p> <p>F Accounting method: <input type="checkbox"/> Cash <input checked="" type="checkbox"/> Accrual <input type="checkbox"/> Other (specify) ▶</p>
--	--	--	---

• Section 501(c)(3) organizations and 4947(a)(1) nonexempt charitable trusts must attach a completed Schedule A (Form 990 or 990-EZ).

H and **I** are not applicable to section 527 organizations.

H(a) Is this a group return for affiliates? Yes No

H(b) If "Yes," enter number of affiliates ▶ N/A

H(c) Are all affiliates included? Yes No
(If "No," attach a list. See instructions.)

H(d) Is this a separate return filed by an organization covered by a group ruling? Yes No

I Group Exemption Number ▶

G Website: ▶ NW.AMFAR.ORG

J Organization type (check only one) 501(c) (3) ◀ (insert no.) 4947(a)(1) or 527

K Check here if the organization's gross receipts are normally not more than \$25,000. The organization need not file a return with the IRS, but if the organization chooses to file a return, be sure to file a complete return. Some states require a complete return.

L Gross receipts: Add lines 6b, 8b, 9b, and 10b to line 12 ▶ 26,528,915.

M Check if the organization is not required to attach Sch. B (Form 990, 990-EZ, or 990-PF).

Part I Revenue, Expenses, and Changes in Net Assets or Fund Balances (See the instructions.)

	1 Contributions, gifts, grants, and similar amounts received:				
	a Direct public support	1a	<u>14,722,323.</u>		
	b Indirect public support	1b			
	c Government contributions (grants)	1c	<u>2,744,284.</u>		
	d Total (add lines 1a through 1c) (cash \$ <u>17,286,314.</u> noncash \$ <u>180,293.</u>)	1d		<u>17,466,607.</u>	
	2 Program service revenue including government fees and contracts (from Part VII, line 93)	2			
	3 Membership dues and assessments	3			
	4 Interest on savings and temporary cash investments	4		<u>211,035.</u>	
	5 Dividends and interest from securities	5		<u>322,511.</u>	
Revenue	6 a Gross rents	6a			
	b Less: rental expenses	6b			
	c Net rental income or (loss) (subtract line 6b from line 6a)	6c			
	7 Other investment income (describe ▶)	7			
	8 a Gross amount from sales of assets other than inventory	(A) Securities 8a	(B) Other 8a	<u>6,911,373.</u>	<u>11,970.</u>
	b Less: cost or other basis and sales expenses	8b	<u>6,915,382.</u>	<u>8,301.</u>	
	c Gain or (loss) (attach schedule)	8c	<u>-4,009.</u>	<u>3,669.</u>	
	d Net gain or (loss) (combine line 8c, columns (A) and (B))	8d		<u>-340.</u>	
	9 Special events and activities (attach schedule). If any amount is from gaming, check here <input type="checkbox"/>				
	a Gross revenue (not including \$ <u>6,366,458.</u> of contributions reported on line 1a)	9a	<u>1,302,937.</u>		
	b Less: direct expenses other than fundraising expenses	9b	<u>1,302,937.</u>		
	c Net income or (loss) from special events (subtract line 9b from line 9a)	9c		<u>NONE</u>	
	10 a Gross sales of inventory, less returns and allowances	10a	<u>144,590.</u>		
	b Less: cost of goods sold	10b	<u>134,549.</u>		
	c Gross profit or (loss) from sales of inventory (attach schedule) (subtract line 10b from line 10a)	10c		<u>10,041.</u>	
	11 Other revenue (from Part VII, line 103)	11		<u>157,892.</u>	
	12 Total revenue (add lines 1d, 2, 3, 4, 5, 6c, 7, 8d, 9c, 10c, and 11)	12		<u>18,167,746.</u>	
Expenses	13 Program services (from line 44, column (B))	13		<u>12,983,025.</u>	
	14 Management and general (from line 44, column (C))	14		<u>1,363,780.</u>	
	15 Fundraising (from line 44, column (D))	15		<u>2,597,830.</u>	
	16 Payments to affiliates (attach schedule)	16			
	17 Total expenses (add lines 13 and 14, column (A))	17		<u>16,944,635.</u>	
Net Assets	18 Excess or (deficit) for the year (subtract line 17 from line 12)	18		<u>1,223,111.</u>	
	19 Net assets or fund balances at beginning of year (from line 73, column (A))	19		<u>13,955,721.</u>	
	20 Other changes in net assets or fund balances (attach explanation)	20		<u>-10,811.</u>	
	21 Net assets or fund balances at end of year (combine lines 18, 19, and 20)	21		<u>15,168,021.</u>	

For Privacy Act and Paperwork Reduction Act Notice, see the separate instructions.

Part II Statement of Functional Expenses All organizations must complete columns (A), (B), (C), and (D) are required for section 501(c)(3) and (4) organizations and section 4947(a)(1) nonexempt charitable trusts but optional for others. (See the instructions.)

Do not include amounts reported on line 8b, 8c, 9b, 10b, or 16 of Part I.		(A) Total	(B) Program services	(C) Management and general	(D) Fundraising
22	Grants and allocations (attach schedule) (cash \$ <u>2,361,279</u> , noncash \$ <u>NONE</u>) If this amount includes foreign grants, check here <input checked="" type="checkbox"/> X	2,361,279.	2,361,279.	STMT 5	
23	Specific assistance to individuals (attach schedule)				
24	Benefits paid to or for members (attach schedule)				STMT 6-7
25	Compensation of officers, directors, etc.	1,519,478.	1,347,962.	93,196.	78,320.
26	Other salaries and wages	3,326,140.	2,312,274.	440,437.	573,429.
27	Pension plan contributions	141,437.	119,855.	5,589.	15,993.
28	Other employee benefits	543,718.	398,020.	96,684.	49,014.
29	Payroll taxes	314,945.	250,657.	16,678.	47,610.
30	Professional fundraising fees	483,030.			483,030.
31	Accounting fees	64,705.		64,705.	
32	Legal fees	55,080.	32,904.	4,714.	17,462.
33	Supplies	55,730.	35,193.	8,699.	11,838.
34	Telephone	156,438.	99,273.	19,279.	37,886.
35	Postage and shipping	730,433.	339,553.	8,508.	382,372.
36	Occupancy	1,053,951.	679,459.	177,241.	197,251.
37	Equipment rental and maintenance	170,841.	110,957.	28,337.	31,547.
38	Printing and publications	784,757.	552,105.	261.	232,391.
39	Travel	524,998.	418,697.	25,105.	81,196.
40	Conferences, conventions, and meetings	718,519.	688,576.	9,088.	20,855.
41	Interest				
42	Depreciation, depletion, etc. (attach schedule)	257,235.	166,215.	43,358.	47,662.
43	Other expenses not covered above (itemize):				
a	STMT 8	3,681,921.	3,070,046.	321,901.	289,974.
b					
c					
d					
e					
f					
g					
44	Total functional expenses. Add lines 22 through 43. (Organizations completing columns (B)-(D), carry these totals to lines 13-15).	16,944,635.	12,983,025.	1,363,780.	2,597,830.

Joint Costs. Check X if you are following SOP 98-2.

Are any joint costs from a combined educational campaign and fundraising solicitation reported in (B) Program services? Yes No
 If "Yes," enter (i) the aggregate amount of these joint costs \$ 1,018,568.; (ii) the amount allocated to Program services \$ 652,136.
 (iii) the amount allocated to Management and general \$ NONE.; and (iv) the amount allocated to Fundraising \$ 366,432.

Part III Statement of Program Service Accomplishments (See the instructions.)

Form 990 is available for public inspection and, for some people, serves as the primary or sole source of information about a particular organization. How the public perceives an organization in such cases may be determined by the information presented on its return. Therefore, please make sure the return is complete and accurate and fully describes, in Part III, the organization's programs and accomplishments.

What is the organization's primary exempt purpose? SEE STATEMENT 9 All organizations must describe their exempt purpose achievements in a clear and concise manner. State the number of clients served, publications issued, etc. Discuss achievements that are not measurable. (Section 501(c)(3) and (4) organizations and 4947(a)(1) nonexempt charitable trusts must also enter the amount of grants and allocations to others.)	Program Service Expenses (Required for 501(c)(3) and (4) orgs., and 4947(a)(1) trusts; but optional for others.)
a RESEARCH - SEE STATEMENT 9 FOR DETAIL ----- ----- ----- ----- ----- (Grants and allocations \$ 2,361,279.) If this amount includes foreign grants, check here <input checked="" type="checkbox"/>	6,105,596.
b GLOBAL INITIATIVES - SEE STATEMENT 9 FOR DETAIL ----- ----- ----- ----- ----- (Grants and allocations \$) If this amount includes foreign grants, check here <input type="checkbox"/>	2,017,165.
c PUBLIC POLICY - SEE STATEMENT 9 FOR DETAIL ----- ----- ----- ----- ----- (Grants and allocations \$) If this amount includes foreign grants, check here <input type="checkbox"/>	1,244,963.
d EDUCATION & INFORMATION - SEE STATEMENT 9 FOR DETAIL ----- ----- ----- ----- ----- (Grants and allocations \$) If this amount includes foreign grants, check here <input type="checkbox"/>	3,615,301.
e Other program services (attach schedule) (Grants and allocations \$) If this amount includes foreign grants, check here <input type="checkbox"/>	
f Total of Program Service Expenses (should equal line 44, column (B), Program services),	12,983,025. Form 990 (2005)

Part IV Balance Sheets (See the instructions.)

		(A) Beginning of year	(B) End of year	
Note: Where required, attached schedules and amounts within the description column should be for end-of-year amounts only.				
Assets	45 Cash - non-interest-bearing	609,449.	935,169.	
	46 Savings and temporary cash investments	6,191,518.	6,055,698.	
	47a Accounts receivable	890,593.		
	b Less: allowance for doubtful accounts	41,858.	848,735.	
	48a Pledges receivable	639,988.		
	b Less: allowance for doubtful accounts	389,770.	250,218.	
	49 Grants receivable			
	50 Receivables from officers, directors, trustees, and key employees (attach schedule)			
	51a Other notes and loans receivable (attach schedule)			
	b Less: allowance for doubtful accounts			
	52 Inventories for sale or use	111,353.	107,900.	
	53 Prepaid expenses and deferred charges	402,422.	275,203.	
	54 Investments - securities (attach schedule) <input type="checkbox"/> Cost <input checked="" type="checkbox"/> FMV	8,451,443.	9,125,691.	
	55a Investments - land, buildings, and equipment: basis			
	b Less: accumulated depreciation (attach schedule)			
56 Investments - other (attach schedule)				
57a Land, buildings, and equipment: basis	2,985,223.			
b Less: accumulated depreciation (attach schedule)	2,031,135.	954,088.		
58 Other assets (describe <input type="checkbox"/> STMT 11)	126,021.	141,939.		
59 Total assets (must equal line 74). Add lines 45 through 58.	17,699,826.	18,694,641.		
Liabilities	60 Accounts payable and accrued expenses	746,136.	922,602.	
	61 Grants payable	1,486,291.	1,034,587.	
	62 Deferred revenue <input type="checkbox"/> STMT 12	934,905.	998,173.	
	63 Loans from officers, directors, trustees, and key employees (attach schedule)			
	64a Tax-exempt bond liabilities (attach schedule)			
	b Mortgages and other notes payable (attach schedule)			
	65 Other liabilities (describe <input type="checkbox"/> STMT 13)	576,773.	571,258.	
66 Total liabilities. Add lines 60 through 65.	3,744,105.	3,526,620.		
Organizations that follow SFAS 117, check here <input checked="" type="checkbox"/> and complete lines 67 through 69 and lines 73 and 74.				
Net Assets or Fund Balances	67 Unrestricted	11,308,936.	11,961,590.	
	68 Temporarily restricted	2,362,009.	2,912,261.	
	69 Permanently restricted	284,776.	294,170.	
	Organizations that do not follow SFAS 117, check here <input type="checkbox"/> and complete lines 70 through 74.			
	70 Capital stock, trust principal, or current funds			
	71 Paid-in or capital surplus, or land, building, and equipment fund			
	72 Retained earnings, endowment, accumulated income, or other funds			
73 Total net assets or fund balances (add lines 67 through 69 or lines 70 through 72; column (A) must equal line 19; column (B) must equal line 21)	13,955,721.	15,168,021.		
74 Total liabilities and net assets/fund balances. Add lines 66 and 73.	17,699,826.	18,694,641.		

Part IV-A Reconciliation of Revenue per Audited Financial Statements With Revenue per Return (See the instructions.)

a	Total revenue, gains, and other support per audited financial statements	a	18,283,209.
b	Amounts included on line a but not on Part I, line 12:		
1	Net unrealized gains on investments	b1	-10,811.
2	Donated services and use of facilities	b2	130,400.
3	Recoveries of prior year grants	b3	
4	Other (specify): _____	b4	
	Add lines b1 through b4	b	119,589.
c	Subtract line b from line a	c	18,163,620.
d	Amounts included on Part I, line 12, but not on line a:		
1	Investment expenses not included on Part I, line 6b	d1	
2	Other (specify): <u>SEE STATEMENT 14</u>	d2	4,126.
	Add lines d1 and d2	d	4,126.
e	Total revenue (Part I, line 12). Add lines c and d.	e	18,167,746.

Part IV-B Reconciliation of Expenses per Audited Financial Statements With Expenses per Return

a	Total expenses and losses per audited financial statements	a	17,070,909.
b	Amounts included on line a but not on Part I, line 17:		
1	Donated services and use of facilities	b1	130,400.
2	Prior year adjustments reported on Part I, line 20	b2	
3	Losses reported on Part I, line 20	b3	
4	Other (specify): _____	b4	
	Add lines b1 through b4	b	130,400.
c	Subtract line b from line a	c	16,940,509.
d	Amounts included on Part I, line 17, but not on line a:		
1	Investment expenses not included on Part I, line 6b	d1	
2	Other (specify): <u>SEE STATEMENT 15</u>	d2	4,126.
	Add lines d1 and d2	d	4,126.
e	Total expenses (Part I, line 17). Add lines c and d.	e	16,944,635.

Part V Current Officers, Directors, Trustees, and Key Employees (List each person who was an officer, director, trustee, or key employee at any time during the year even if they were not compensated.) (See the instructions.)

(A) Name and address	(B) Title and average hours per week devoted to position	(C) Compensation (if not paid, enter -0-)	(D) Contributions to employee benefit plans & deferred compensation plans	(E) Expense account and other allowances
SEE STATEMENT 16-21		1,298,629.	178,680.	NONE

Part V-A Current Officers, Directors, Trustees, and Key Employees (continued)		Yes	No
75a	Enter the total number of officers, directors, and trustees permitted to vote on organization business at board meetings 22		
b	Are any officers, directors, trustees, or key employees listed in Form 990, Part V-A, or highest compensated employees listed in Schedule A, Part I, or highest compensated professional and other independent contractors listed in Schedule A, Part II-A or II-B, related to each other through family or business relationships? If "Yes," attach a statement that identifies the individuals and explains the relationship(s)	75b	X
c	Do any officers, directors, trustees, or key employees listed in Form 990, Part V-A, or highest compensated employees listed in Schedule A, Part I, or highest compensated professional and other independent contractors listed in Schedule A, Part II-A or II-B, receive compensation from any other organizations, whether tax exempt or taxable, that are related to this organization through common supervision or common control? Note. Related organizations include section 509(a)(3) supporting organizations. If "Yes," attach a statement that identifies the individuals, explains the relationship between this organization and the other organization(s), and describes the compensation arrangements, including amounts paid to each individual by each related organization.	75c	X
d	Does the organization have a written conflict of interest policy?	75d	X

Part V-B Former Officers, Directors, Trustees, and Key Employees That Received Compensation or Other Benefits (If any former officer, director, trustee, or key employee received compensation or other benefits (described below) during the year, list that person below and enter the amount of compensation or other benefits in the appropriate column. See the instructions.)

(A) Name and address	(B) Loans and Advances	(C) Compensation	(D) Contributions to employee benefit plans & deferred compensation plans	(E) Expense account and other allowances
SEE STATEMENT 22	NONE	42,168.	NONE	NONE

Part VI Other Information (See the instructions.)		Yes	No
76	Did the organization engage in any activity not previously reported to the IRS? If "Yes," attach a detailed description of each activity	76	X
77	Were any changes made in the organizing or governing documents but not reported to the IRS? If "Yes," attach a conformed copy of the changes.	77	X
78a	Did the organization have unrelated business gross income of \$1,000 or more during the year covered by this return?	78a	X
b	If "Yes," has it filed a tax return on Form 990-T for this year?	78b	N/A
79	Was there a liquidation, dissolution, termination, or substantial contraction during the year? If "Yes," attach a statement	79	X
80a	Is the organization related (other than by association with a statewide or nationwide organization) through common membership, governing bodies, trustees, officers, etc., to any other exempt or nonexempt organization?	80a	X
b	If "Yes," enter the name of the organization ▶ and check whether it is <input type="checkbox"/> exempt or <input type="checkbox"/> nonexempt		
81a	Enter direct and indirect political expenditures. (See line 81 instructions.). 81a NONE		
b	Did the organization file Form 1120-POL for this year?	81b	X

Part VI Other Information (continued)

		Yes	No
82a	Did the organization receive donated services or the use of materials, equipment, or facilities at no charge or at substantially less than fair rental value?	X	
b	If "Yes," you may indicate the value of these items here. Do not include this amount as revenue in Part I or as an expense in Part II. (See instructions in Part III.)		
82b			130,400.
83a	Did the organization comply with the public inspection requirements for returns and exemption applications?	X	
b	Did the organization comply with the disclosure requirements relating to quid pro quo contributions?	X	
84a	Did the organization solicit any contributions or gifts that were not tax deductible?	N/A	
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?	N/A	
85	501(c)(4), (5), or (6) organizations: a Were substantially all dues nondeductible by members?	N/A	
b	Did the organization make only in-house lobbying expenditures of \$2,000 or less? If "Yes" was answered to either 85a or 85b, do not complete 85c through 85h below unless the organization received a waiver for proxy tax owed for the prior year.	N/A	
c	Dues, assessments, and similar amounts from members	85c	N/A
d	Section 162(e) lobbying and political expenditures	85d	N/A
e	Aggregate nondeductible amount of section 6033(e)(1)(A) dues notices	85e	N/A
f	Taxable amount of lobbying and political expenditures (line 85d less 85e)	85f	N/A
g	Does the organization elect to pay the section 6033(e) tax on the amount on line 85f?	85g	N/A
h	If section 6033(e)(1)(A) dues notices were sent, does the organization agree to add the amount on line 85f to its reasonable estimate of dues allocable to nondeductible lobbying and political expenditures for the following tax year?	85h	N/A
86	501(c)(7) orgs. Enter: a Initiation fees and capital contributions included on line 12	86a	N/A
b	Gross receipts, included on line 12, for public use of club facilities	86b	N/A
87	501(c)(12) orgs. Enter: a Gross income from members or shareholders	87a	N/A
b	Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.)	87b	N/A
88	At any time during the year, did the organization own a 50% or greater interest in a taxable corporation or partnership, or an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If "Yes," complete Part IX.	88	X
89a	501(c)(3) organizations. Enter: Amount of tax imposed on the organization during the year under: section 4911 ▶ NONE ; section 4912 ▶ NONE ; section 4955 ▶ NONE		
b	501(c)(3) and 501(c)(4) orgs. Did the organization engage in any section 4958 excess benefit transaction during the year or did it become aware of an excess benefit transaction from a prior year? If "Yes," attach a statement explaining each transaction	89b	X
c	Enter: Amount of tax imposed on the organization managers or disqualified persons during the year under sections 4912, 4955, and 4958		NONE
d	Enter: Amount of tax on line 89c, above, reimbursed by the organization		NONE
90a	List the states with which a copy of this return is filed ▶ SEE STATEMENT 23		
b	Number of employees employed in the pay period that includes March 12, 2005 (See instructions.)	90b	66
91a	The books are in care of ▶ SCOTT NEWMAN Telephone no. ▶ 212-806-1703 Located at ▶ 120 WALL ST., 13TH FLOOR, NEW YORK, NY ZIP + 4 ▶ 10005-3908		
b	At any time during the calendar year, did the organization have an interest in or a signature or other authority over a financial account in a foreign country (such as a bank account, securities account, or other financial account)? If "Yes," enter the name of the foreign country ▶ See the instructions for exceptions and filing requirements for Form TD F 90-22.1, Report of Foreign Bank and Financial Accounts.	91b	X
c	At any time during the calendar year, did the organization maintain an office outside of the United States? If "Yes," enter the name of the foreign country ▶ THAILAND	91c	X
92	Section 4947(a)(1) nonexempt charitable trusts filing Form 990 in lieu of Form 1041 - Check here and enter the amount of tax-exempt interest received or accrued during the tax year ▶ 92		N/A

Part VII Analysis of Income-Producing Activities (See the instructions.)

Note: Enter gross amounts unless otherwise indicated.

	Unrelated business income		Excluded by section 512, 513, or 514		(E) Related or exempt function income
	(A) Business code	(B) Amount	(C) Exclusion code	(D) Amount	
93 Program service revenue:					
a _____					
b _____					
c _____					
d _____					
e _____					
f Medicare/Medicaid payments					
g Fees and contracts from government agencies					
94 Membership dues and assessments					
95 Interest on savings and temporary cash investments			14	211,035.	
96 Dividends and interest from securities			14	322,511.	
97 Net rental income or (loss) from real estate:					
a debt-financed property					
b not debt-financed property					
98 Net rental income or (loss) from personal property					
99 Other investment income					
100 Gain or (loss) from sales of assets other than inventory			18	-340.	
101 Net income or (loss) from special events			01	NONE	
102 Gross profit or (loss) from sales of inventory			05	10,041.	
103 Other revenue: a _____					
b MISCELLANEOUS			01	3,367.	
c LIST RENTAL			01	17,642.	
d ROYALTIES			15	136,883.	
e _____					
104 Subtotal (add columns (B), (D), and (E))				701,139.	
105 Total (add line 104, columns (B), (D), and (E))					701,139.

Note: Line 105 plus line 1d, Part I, should equal the amount on line 12, Part I.

Part VIII Relationship of Activities to the Accomplishment of Exempt Purposes (See the instructions.)

Line No.	Explain how each activity for which income is reported in column (E) of Part VII contributed importantly to the accomplishment of the organization's exempt purposes (other than by providing funds for such purposes).
▼	

Part IX Information Regarding Taxable Subsidiaries and Disregarded Entities (See the instructions.)


(A) Name, address, and EIN of corporation, partnership, or disregarded entity	(B) Percentage of ownership interest	(C) Nature of activities	(D) Total income	(E) End-of-year assets
	%			
	%			
	%			
	%			

Part X Information Regarding Transfers Associated with Personal Benefit Contracts (See the instructions.)

- (a) Did the organization, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract? Yes No
- (b) Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract? Yes No
- Note: If "Yes" to (b), file Form 8870 and Form 4720 (see instructions).



Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Please Sign Here

Signature of officer:  Date: 12/8/07

Type or print name and title: Scott Newman, Asst. Treasurer, VP, Finance & Admin.

Paid Preparer's Use Only

Preparer's signature:  Date: 02.07.07 Check if self-employed: Preparer's SSN or PTIN (See Gen. Inst. W): 

Firm's name (or yours if self-employed), address, and ZIP + 4: PRICewaterhouseCOOPERS LLP, 350 SOUTH GRAND AVENUE, LOS ANGELES, CA 90071-3405

EIN: 13-4008324 Phone no.: 213-356-6000

SCHEDULE A
(Form 990 or 990-EZ)

Organization Exempt Under Section 501(c)(3)

(Except Private Foundation) and Section 501(e), 501(f), 501(k), 501(n),
or 4947(a)(1) Nonexempt Charitable Trust

OMB No. 1545-0047

2005

Department of the Treasury
Internal Revenue Service

Supplementary Information - (See separate instructions.)

▶ **MUST be completed by the above organizations and attached to their Form 990 or 990-EZ**

Name of the organization **THE FOUNDATION FOR AIDS RESEARCH**
(DBA AMFAR, AIDS RESEARCH FOUNDATION)

Employer identification number
13-3163817

Part I Compensation of the Five Highest Paid Employees Other Than Officers, Directors, and Trustees
(See page 1 of the instructions. List each one. If there are none, enter "None.")

(a) Name and address of each employee paid more than \$50,000	(b) Title and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans & deferred compensation	(e) Expense account and other allowances
SEE STATEMENT 24				

Total number of other employees paid over \$50,000 . . . ▶ **23**

Part II-A Compensation of the Five Highest Paid Independent Contractors for Professional Services
(See page 2 of the instructions. List each one (whether individuals or firms). If there are none, enter "None.")

(a) Name and address of each independent contractor paid more than \$50,000	(b) Type of service	(c) Compensation
FERN C. PORTNOY NEW YORK, NY 10023	FUNDRAISING COUNSEL	181,500.
DR. JEFFREY LAURENCE, M.D. GREENWICH, CT 06831	SCIENTIFIC CONSULT.	80,760.
KEVIN L. CONNOR SEBASTOPOL, CA 95472	INFO. TECH CONSULT.	76,000.
PRICENWATERHOUSECOOPERS LLP NEW YORK, NY 10017	AUDIT AND TAX SERV.	64,705.

Total number of others receiving over \$50,000 for professional services . . . ▶ **NONE**

Part II-B Compensation of the Five Highest Paid Independent Contractors for Other Services
(List each contractor who performed services other than professional services, whether individuals or firms. If there are none, enter "None." See page 2 of the instructions.)

(a) Name and address of each independent contractor paid more than \$50,000	(b) Type of service	(c) Compensation
AAB PRODUCTIONS NEW YORK, NY 10002	EVENT PRODUCTION	128,600.

Total number of other contractors receiving over \$50,000 for other services . . . ▶ **NONE**

For Paperwork Reduction Act Notice, see the Instructions for Form 990 and Form 990-EZ.

Schedule A (Form 990 or 990-EZ) 2005

Part III Statements About Activities (See page 2 of the instructions.)		Yes	No
1	During the year, has the organization attempted to influence national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum? If "Yes," enter the total expenses paid or incurred in connection with the lobbying activities ▶ \$ <u>320,227.</u> (Must equal amounts on line 38, Part VI-A, or line I of Part VI-B.)	X	
Organizations that made an election under section 501(h) by filing Form 5768 must complete Part VI-A. Other organizations checking "Yes" must complete Part VI-B AND attach a statement giving a detailed description of the lobbying activities.			
2	During the year, has the organization, either directly or indirectly, engaged in any of the following acts with any substantial contributors, trustees, directors, officers, creators, key employees, or members of their families, or with any taxable organization with which any such person is affiliated as an officer, director, trustee, majority owner, or principal beneficiary? (If the answer to any question is "Yes," attach a detailed statement explaining the transactions.)		
a	Sale, exchange, or leasing of property?		X
b	Lending of money or other extension of credit?		X
c	Furnishing of goods, services, or facilities?		X
d	Payment of compensation (or payment or reimbursement of expenses if more than \$1,000)? . FORM 990, PART V	X	
e	Transfer of any part of its income or assets?		X
3a	Do you make grants for scholarships, fellowships, student loans, etc.? (If "Yes," attach an explanation of how you determine that recipients qualify to receive payments.)	X	
b	Do you have a section 403(b) annuity plan for your employees?	X	
c	During the year, did the organization receive a contribution of qualified real property interest under section 170(h)?		X
4a	Did you maintain any separate account for participating donors where donors have the right to provide advice on the use or distribution of funds?		X
b	Do you provide credit counseling, debt management, credit repair, or debt negotiation services?		X

Part IV Reason for Non-Private Foundation Status (See pages 3 through 6 of the instructions.)

The organization is not a private foundation because it is: (Please check only ONE applicable box.)

5 A church, convention of churches, or association of churches. Section 170(b)(1)(A)(i).

6 A school. Section 170(b)(1)(A)(ii). (Also complete Part V.)

7 A hospital or a cooperative hospital service organization. Section 170(b)(1)(A)(iii).

8 A Federal, state, or local government or governmental unit. Section 170(b)(1)(A)(iv).

9 A medical research organization operated in conjunction with a hospital. Section 170(b)(1)(A)(v). Enter the hospital's name, city, and state ▶ _____

10 An organization operated for the benefit of a college or university owned or operated by a governmental unit. Section 170(b)(1)(A)(vi). (Also complete the Support Schedule in Part IV-A.)

11a An organization that normally receives a substantial part of its support from a governmental unit or from the general public. Section 170(b)(1)(A)(vii). (Also complete the Support Schedule in Part IV-A.)

11b A community trust. Section 170(b)(1)(A)(viii). (Also complete the Support Schedule in Part IV-A.)

12 An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its charitable, etc., functions - subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Also complete the Support Schedule in Part IV-A.)

13 An organization that is not controlled by any disqualified persons (other than foundation managers) and supports organizations described in: (1) lines 5 through 12 above; or (2) section 501(c)(4), (5), or (6), if they meet the test of section 509(a)(2). Check the box that describes the type of supporting organization: ▶ Type 1 Type 2 Type 3

Provide the following information about the supported organizations. (See page 6 of the instructions.)

(a) Name(s) of supported organization(s)	(b) Line number from above

14 An organization organized and operated to test for public safety. Section 509(a)(4). (See page 6 of the instructions.)

Part IV-A Support Schedule (Complete only if you checked a box on line 10, 11, or 12.) *Use cash method of accounting.*

Note: You may use the worksheet in the instructions for converting from the accrual to the cash method of accounting.

Calendar year (or fiscal year beginning in)	(a) 2004	(b) 2003	(c) 2002	(d) 2001	(e) Total
15 Gifts, grants, and contributions received. (Do not include unusual grants. See line 28.)	17,103,604.	14,990,128.	12,830,057.	17,120,620.	62,044,409.
16 Membership fees received					
17 Gross receipts from admissions, merchandise sold or services performed, or furnishing of facilities in any activity that is related to the organization's charitable, etc., purpose	2,048,215.	1,746,687.	1,551,709.	1,874,205.	7,220,816.
18 Gross income from interest, dividends, amounts received from payments on securities loans (section 512(a)(5)), rents, royalties, and unrelated business taxable income (less section 511 taxes) from businesses acquired by the organization after June 30, 1975	638,330.	642,104.	906,437.	325,189.	2,512,060.
19 Net income from unrelated business activities not included in line 18					
20 Tax revenues levied for the organization's benefit and either paid to it or expended on its behalf					
21 The value of services or facilities furnished to the organization by a governmental unit without charge. Do not include the value of services or facilities generally furnished to the public without charge					
22 Other income. Attach a schedule. Do not include gain or (loss) from sale of capital assets	STMT 26 28,009.	74,226.	80,292.	58,772.	241,299.
23 Total of lines 15 through 22	19,818,158.	17,453,145.	15,368,495.	19,378,786.	72,018,584.
24 Line 23 minus line 17.	17,769,943.	15,706,458.	13,816,786.	17,504,581.	64,797,768.
25 Enter 1% of line 23.	198,182.	174,531.	153,685.	193,788.	
26 Organizations described on lines 10 or 11: a Enter 2% of amount in column (e), line 24					26a 1,295,955.
b Prepare a list for your records to show the name of and amount contributed by each person (other than a governmental unit or publicly supported organization) whose total gifts for 2001 through 2004 exceeded the amount shown in line 26a. Do not file this list with your return. Enter the total of all these excess amounts					26b 7,936,542.
c Total support for section 509(a)(1) test: Enter line 24, column (e)					26c 64,797,768.
d Add: Amounts from column (e) for lines: 18 2,512,060., 19 _____, 22 241,299., 26b 7,936,542.					26d 10,689,901.
e Public support (line 26c minus line 26d total)					26e 54,107,867.
f Public support percentage (line 26e (numerator) divided by line 26c (denominator))					26f 83.5027 %
27 Organizations described on line 12: a For amounts included in lines 15, 16, and 17 that were received from a "disqualified person," prepare a list for your records to show the name of, and total amounts received in each year from, each "disqualified person." Do not file this list with your return. Enter the sum of such amounts for each year: NOT APPLICABLE (2004) _____ (2003) _____ (2002) _____ (2001) _____					
b For any amount included in line 17 that was received from each person (other than "disqualified persons"), prepare a list for your records to show the name of, and amount received for each year, that was more than the larger of (1) the amount on line 25 for the year or (2) \$5,000. (Include in the list organizations described in lines 5 through 11, as well as individuals.) Do not file this list with your return. After computing the difference between the amount received and the larger amount described in (1) or (2), enter the sum of these differences (the excess amounts) for each year: (2004) _____ (2003) _____ (2002) _____ (2001) _____					
c Add: Amounts from column (a) for lines: 15 _____ 16 _____ 17 _____ 20 _____ 21 _____					27c _____
d Add: Line 27a total _____ and line 27b total _____					27d _____
e Public support (line 27c total minus line 27d total)					27e _____
f Total support for section 509(a)(2) test: Enter amount from line 23, column (e)					27f _____
g Public support percentage (line 27e (numerator) divided by line 27f (denominator))					27g _____ %
h Investment income percentage (line 18, column (e) (numerator) divided by line 27f (denominator))					27h _____ %
28 Unusual Grants: For an organization described in line 10, 11, or 12 that received any unusual grants during 2001 through 2004, prepare a list for your records to show, for each year, the name of the contributor, the date and amount of the grant, and a brief description of the nature of the grant. Do not file this list with your return. Do not include these grants in line 15.					

Part V Private School Questionnaire (See page 7 of the instructions.) NOT APPLICABLE
 (To be completed ONLY by schools that checked the box on line 6 in Part IV)

		Yes	No
29	Does the organization have a racially nondiscriminatory policy toward students by statement in its charter, bylaws, other governing instrument, or in a resolution of its governing body?		
30	Does the organization include a statement of its racially nondiscriminatory policy toward students in all its brochures, catalogues, and other written communications with the public dealing with student admissions, programs, and scholarships?		
31	Has the organization publicized its racially nondiscriminatory policy through newspaper or broadcast media during the period of solicitation for students, or during the registration period if it has no solicitation program, in a way that makes the policy known to all parts of the general community it serves?		
	If "Yes," please describe; if "No," please explain. (If you need more space, attach a separate statement.) ----- ----- -----		
32	Does the organization maintain the following:		
a	Records indicating the racial composition of the student body, faculty, and administrative staff?		
b	Records documenting that scholarships and other financial assistance are awarded on a racially nondiscriminatory basis?		
c	Copies of all catalogues, brochures, announcements, and other written communications to the public dealing with student admissions, programs, and scholarships?		
d	Copies of all material used by the organization or on its behalf to solicit contributions?		
	If you answered "No" to any of the above, please explain. (If you need more space, attach a separate statement.) ----- -----		
33	Does the organization discriminate by race in any way with respect to:		
a	Students' rights or privileges?		
b	Admissions policies?		
c	Employment of faculty or administrative staff?		
d	Scholarships or other financial assistance?		
e	Educational policies?		
f	Use of facilities?		
g	Athletic programs?		
h	Other extracurricular activities?		
	If you answered "Yes" to any of the above, please explain. (If you need more space, attach a separate statement.) ----- -----		
34a	Does the organization receive any financial aid or assistance from a governmental agency?		
b	Has the organization's right to such aid ever been revoked or suspended?		
	If you answered "Yes" to either 34a or b, please explain using an attached statement.		
35	Does the organization certify that it has complied with the applicable requirements of sections 4.01 through 4.05 of Rev. Proc. 75-50, 1975-2 C.B. 587, covering racial nondiscrimination? If "No," attach an explanation		

Part VI-A Lobbying Expenditures by Electing Public Charities (See page 9 of the instructions.)
 (To be completed ONLY by an eligible organization that filed Form 5768)

Check a if the organization belongs to an affiliated group. Check b if you checked "a" and "limited control" provisions apply.

Limits on Lobbying Expenditures		(a) Affiliated group totals	(b) To be completed for ALL electing organizations
(The term "expenditures" means amounts paid or incurred.)			
36	Total lobbying expenditures to influence public opinion (grassroots lobbying)	36	13,122.
37	Total lobbying expenditures to influence a legislative body (direct lobbying)	37	307,105.
38	Total lobbying expenditures (add lines 36 and 37)	38	320,227.
39	Other exempt purpose expenditures	39	16,624,408.
40	Total exempt purpose expenditures (add lines 38 and 39)	40	16,944,635.
41	Lobbying nontaxable amount. Enter the amount from the following table - If the amount on line 40 is - The lobbying nontaxable amount is - Not over \$500,000 20% of the amount on line 40 Over \$500,000 but not over \$1,000,000 . . . \$100,000 plus 15% of the excess over \$500,000 Over \$1,000,000 but not over \$1,500,000 . . \$175,000 plus 10% of the excess over \$1,000,000 Over \$1,500,000 but not over \$17,000,000 . \$225,000 plus 5% of the excess over \$1,500,000 Over \$17,000,000 \$1,000,000	41	997,232.
42	Grassroots nontaxable amount (enter 25% of line 41)	42	249,308.
43	Subtract line 42 from line 36. Enter -0- if line 42 is more than line 36	43	
44	Subtract line 41 from line 38. Enter -0- if line 41 is more than line 38	44	

Caution: If there is an amount on either line 43 or line 44, you must file Form 4720.

4-Year Averaging Period Under Section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below.
 See the instructions for lines 45 through 50 on page 11 of the instructions.)

Calendar year (or fiscal year beginning in) ▶	Lobbying Expenditures During 4-Year Averaging Period					
	(a) 2005	(b) 2004	(c) 2003	(d) 2002	(e) Total	
45	Lobbying nontaxable amount	997,232.	984,630.	760,685.	846,390.	3,588,937.
46	Lobbying ceiling amount (150% of line 45(e))					5,383,406.
47	Total lobbying expenditures	320,227.	424,129.	377,310.	220,519.	1,342,185.
48	Grassroots nontaxable amount	249,308.	246,158.	190,171.	211,598.	897,235.
49	Grassroots ceiling amount (150% of line 48(e))					1,345,853.
50	Grassroots lobbying expenditures	13,122.	154,430.	108,090.	98,778.	374,420.

Part VI-B Lobbying Activity by Nonelecting Public Charities NOT APPLICABLE
 (For reporting only by organizations that did not complete Part VI-A) (See page 11 of the instructions.)

During the year, did the organization attempt to influence national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:	Yes	No	Amount
a Volunteers			
b Paid staff or management (Include compensation in expenses reported on lines c through h.)			
c Media advertisements			
d Mailings to members, legislators, or the public			
e Publications, or published or broadcast statements			
f Grants to other organizations for lobbying purposes			
g Direct contact with legislators, their staffs, government officials, or a legislative body			
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any other means			
i Total lobbying expenditures (Add lines c through h.)			

If "Yes" to any of the above, also attach a statement giving a detailed description of the lobbying activities.

Part VII Information Regarding Transfers To and Transactions and Relationships With Noncharitable Exempt Organizations (See page 12 of the instructions.)

51 Did the reporting organization directly or indirectly engage in any of the following with any other organization described in section 501(c) of the Code (other than section 501(c)(3) organizations) or in section 527, relating to political organizations?

a Transfers from the reporting organization to a noncharitable exempt organization of:

	Yes	No
(i) Cash		X
(ii) Other assets		X
b Other transactions:		
(i) Sales or exchanges of assets with a noncharitable exempt organization		X
(ii) Purchases of assets from a noncharitable exempt organization		X
(iii) Rental of facilities, equipment, or other assets		X
(iv) Reimbursement arrangements		X
(v) Loans or loan guarantees		X
(vi) Performance of services or membership or fundraising solicitations		X
c Sharing of facilities, equipment, mailing lists, other assets, or paid employees		X

d If the answer to any of the above is "Yes," complete the following schedule. Column (b) should always show the fair market value of the goods, other assets, or services given by the reporting organization. If the organization received less than fair market value in any transaction or sharing arrangement, show in column (d) the value of the goods, other assets, or services received:

(a) Line no.	(b) Amount involved	(c) Name of noncharitable exempt organization	(d) Description of transfers, transactions, and sharing arrangements
N/A			

52a Is the organization directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) of the Code (other than section 501(c)(3)) or in section 527? Yes No
b if "Yes," complete the following schedule:

(a) Name of organization	(b) Type of organization	(c) Description of relationship
N/A		

Schedule of Contributors

2005

Supplementary Information for
line 1 of Form 990, 990-EZ, and 990-PF (see instructions)

Name of organization

THE FOUNDATION FOR AIDS RESEARCH
(DBA AMFAR, AIDS RESEARCH FOUNDATION)

Employer identification number

13-3163817

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)(3) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule. (Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule - see instructions.)

General Rule -

For organizations filing Form 990, 990-EZ, or 990-PF that received, during the year, \$5,000 or more (in money or property) from any one contributor. (Complete Parts I and II.)

Special Rules -

For a section 501(c)(3) organization filing Form 990, or Form 990-EZ, that met the 33 1/3% support test under Regulations sections 1.509(a)-3/1.170A-9(e) and received from any one contributor, during the year, a contribution of the greater of \$5,000 or 2% of the amount on line 1 of these forms. (Complete Parts I and II.)

For a section 501(c)(7), (8), or (10) organization filing Form 990, or Form 990-EZ, that received from any one contributor, during the year, aggregate contributions or bequests of more than \$1,000 for use exclusively for religious, charitable, scientific, literary, or educational purposes, or the prevention of cruelty to children or animals. (Complete Parts I, II, and III.)

For a section 501(c)(7), (8), or (10) organization filing Form 990, or Form 990-EZ, that received from any one contributor, during the year, some contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did not aggregate to more than \$1,000. (If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the Parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions of \$5,000 or more during the year.) ▶ \$ _____

Caution: Organizations that are not covered by the General Rule and/or the Special Rules do not file Schedule B (Form 990, 990-EZ, or 990-PF), but they must check the box in the heading of their Form 990, Form 990-EZ, or on line 2 of their Form 990-PF, to certify that they do not meet the filing requirements of Schedule B (Form 990, 990-EZ, or 990-PF).

**INFORMATION NOT OPEN TO PUBLIC
INSPECTION WAS REMOVED.**

THE FOUNDATION FOR AIDS RESEARCH
 Schedule D Detail of Short-term Capital Gains and Losses

13-3163817

Description	Date Acquired	Date Sold	Gross Sales Price	Cost or Other Basis	Short-term Gain/Loss
CAPITAL GAINS (LOSSES) FROM SECURITIES					
REDEMPTION OF U.S. GOVERNMENT TREAS. MUTUAL FUNDS	VAR	VAR	4,387,000.	4,376,507.	10,493.
REDEMPTION OF CERT. OF DEPOSIT DONATED EQUITIES	VAR	VAR	972,388.	983,213.	-10,825.
	VAR	VAR	1,392,000.	1,392,000.	
	VAR	VAR	159,985.	163,662.	-3,677.
TOTAL CAPITAL GAINS (LOSSES) FROM SECURITIES			6,911,373.	6,915,382.	-4,009.
Totals			6,911,373.	6,915,382.	-4,009.

FORM 990, PART I - SPECIAL FUNDRAISING EVENTS AND ACTIVITIES

DESCRIPTION	GROSS REVENUE	DIRECT EXPENSES	NET INCOME
CINEMA AGAINST AIDS CANNES	4,047,231.	618,288.	3,428,943.
DALLAS 2X2 ART EVENT	2,160,490.	323,581.	1,836,909.
SAN FRANCISCO FALL DINNER	444,569.	62,864.	381,705.
HONORING WITH PRIDE	366,449.	115,539.	250,910.
ALL OTHER EVENTS	650,656.	182,665.	467,991.
LESS CONTRIBUTIONS	-6,366,458.		-6,366,458.
TOTALS	1,302,937.	1,302,937.	NONE

The Foundation conducts special events in which a portion of the gross revenue received from attendees represents compensation to the Foundation for the direct cost of benefits (typically food, beverages and entertainment) received by the attendees at the events. The fair value of meals and entertainment provided at special events is measured by the cost to the Foundation. The Foundation accounts for these benefits as an exchange transaction in which the cost of the benefits is balanced by the corresponding revenue. In Fiscal 2006, the Foundation reported special events revenue of \$6,366,458, exchange transaction revenue and exchange transaction expense of \$1,302,937.

FORM 990, PART I - GROSS SALES LESS RETURNS AND ALLOWANCES
=====

DESCRIPTION -----	AMOUNT -----
SALES OF INVENTORY	144,590.
TOTAL	----- 144,590. =====

FORM 990, PART I - OTHER DECREASES IN FUND BALANCES
=====

DESCRIPTION -----	AMOUNT -----
UNREALIZED LOSS ON INVESTMENTS	10,811. -----
TOTAL	10,811. =====

amfAR - The Foundation For AIDS Research
 Schedule of Grant Awards and Expense
 Fiscal year 2006
 10/1/2005 - 9/30/2006

13-3163817

Cycle/ Program Branch	Grant Id and Name	Location	Period of Performance	Awards	Grant Expense
33 RPHC	106466 National Cancer Institute	Frederick, MD	01-Aug-03	0	0
33 RPHC	106464 University of Pennsylvania Medical School	Philadelphia, PA	01-Jan-03	0	0
34 RFGN	106426 University of California, San Francisco	San Francisco, CA	01-Jul-03	0	5,500
34 RFGN	106437 University of Pennsylvania	Philadelphia, PA	01-Jul-03	0	0
34 RPHC	106438 Mount Sinai School of Medicine	New York, NY	01-Jul-03	0	0
34 RPHC	106427 Scripps Research Institute	La Jolla, CA	01-Jul-03	0	0
34 RPHC	106436 Scripps Research Institute	La Jolla, CA	01-Jul-03	0	0
34 RPHC	106457 Wayne State University School of Medicine	Detroit, MI	01-Jul-03	0	0
35 RGGN	106532 Case Western Reserve University	Cleveland, OH	01-Jul-03	0	0
35 RPHF	106524 Trustees of Columbia University in the City of New York	New York, NY	01-Mar-04	0	20,625
35 RPHF	106525 The J. David Gladstone Institutes	New York, NY	01-Mar-04	0	20,625
35 RPHC	106523 Oregon Health and Science University	San Francisco, CA	01-Mar-04	0	20,625
35 RGGN	106582 University of Toronto	Portland, OR	01-Mar-04	0	20,625
35 RGGN	106514 University of Massachusetts Medical School	Toronto, Canada	01-Mar-04	0	11,028
35 RGGN	106520 University of Massachusetts Medical School	Worcester, MA	01-Mar-04	0	0
36 RPHC	106594 Fred Hutchinson Cancer Research Center	Worcester, MA	01-Mar-04	0	0
36 RPHC	106584 University of California, San Francisco	Seattle, WA	01-Mar-04	0	0
36 RPHC	106585 University of Massachusetts Medical School	San Francisco, CA	01-Oct-04	0	48,500
36 RPHC	106598 National AIDS Research Institute	Worcester, MA	01-Oct-04	0	48,500
36 RGGN	106547 Scripps Research Institute	Pune, India	01-Dec-05	9,600	8,250
36 RGGN	106547 Case Western Reserve University	La Jolla, CA	01-Oct-04	0	48,500
36 RGGN	106603 University of Oxford	Cleveland, OH	01-Oct-04	0	0
36 RGHF	106551 Lady Davis Institute for Medical Research	Oxford, England	01-Oct-04	0	0
36 RGHF	106562 The Salk Institute for Biological Studies	Montreal, Canada	01-Oct-04	0	0
36 RGHF	106564 Trustees of Columbia University in the City of New York	La Jolla, CA	01-Oct-04	0	0
36 RGHF	106573 California Institute of Technology	New York, NY	01-Oct-04	0	0
36 RGHF	106610 MacFarlane Burnet Institute for Medical Research	Persepolis, CA	01-Oct-04	0	0
36 RGHF	106559 Centre National de la Recherche Scientifique	Melbourne, Australia	01-Feb-05	0	22,500
36 RGHF	106635 Salk Institute for Biological Studies	Paris, France	01-Oct-04	0	11,250
36 RPHF	106637 Kings College London	La Jolla, CA	01-Jul-05	0	48,500
36 RPHF	106643 University of Utah	London, England	01-Jul-05	0	48,500
36 RPHF	106646 Vanderbilt University Medical School	Salt Lake City, UT	01-Jul-05	0	48,500
36 RPHF	106648 Trustees of Columbia University in the City of New York	Nashville, TN	01-Jul-05	0	48,500
36 RPHC	106642 CIR Institute of Biomedical Research	New York, NY	01-Jul-05	0	48,500
36 RPHC	106634 Universite de Montreal	Boston, MA	01-Jul-05	0	48,500
36 RPHC	106636 UMC at Chapel Hill - Lineberger Cancer Center	Montreal, Canada	01-Jul-05	0	41,550
36 RPHC	106639 Case Western University - Department of Molecular Science	Chapel Hill, NC	01-Jul-05	0	48,500
36 RGHF	106622 Fred Hutchinson Cancer Research Center	Cleveland, OH	01-Jul-05	0	48,500
36 RGHF	106630 Vanderbilt University Medical School	Seattle, WA	01-Jul-05	0	67,500
36 RGHF	106687 Emory University	Nashville, TN	01-Jul-05	0	67,500
36 RPHC	106693 University of North Carolina at Chapel Hill	Atlanta, GA	01-Jan-06	99,000	37,125
36 RPHC		Chapel Hill, NC	01-Jan-06	99,000	37,125

amfAR - The Foundation For AIDS Research
 Schedule of Grant Awards and Expense
 Fiscal year 2006
 10/1/2005 - 9/30/2006

13-3163817

Program	Cycle/ Branch	Grant Id and Name	Location	Period of Performance	Awards	Grant Expense
	39 R/NT	106663 Beth Israel Deaconess Medical Center	Boston, MA	01-Jan-06	90,000	37,125
	39 R/NT	106660 Beckman Research Institute of the City of Hope	Duarte, CA	01-Jan-06	90,000	37,125
	39 R/HT	106660 Mount Sinai School of Medicine	New York, NY	01-Jan-06	90,000	67,500
	39 R/HT	106665 Northwestern University	Chicago, IL	01-Jan-06	90,000	67,500
	39 R/HT	106669 St Vincent's Institute	Fitzroy, Australia	01-Jan-06	90,000	67,500
	39 R/HT	106675 University of Wisconsin-Madison	Madison, WI	01-Jan-06	90,000	67,500
	39 R/HT	106677 Brigham and Women's Hospital/Harvard Medical School	Boston, MA	01-Jan-06	90,000	67,500
	39 R/WA	106670 Brown University	Providence, RI	01-Jan-06	90,000	67,500
	40 R/RL	106729 University of California, San Diego	San Diego, CA	01-Jan-06	57,987	24,161
	40 R/RL	106731 The Sir William Dunn School of Pathology, University of Oxford	Oxford, England	30-Jan-08	125,000	55,624
	40 R/RL	106736 The J.David Gladstone Institutes	San Francisco, CA	01-Jul-06	124,882	15,609
	40 R/RL	106740 Macfarlane Burnet Institute for Medical Research and Public Health	Melbourne, Australia	01-Jul-06	125,000	15,624
	40 R/SM	106715 Monash University	Melbourne, Australia	30-Jan-08	125,000	15,624
	40 R/HT	106718 Case Western Reserve University	Cleveland, OH	01-Jul-06	120,000	30,000
				30-Jan-07	120,000	30,000
				01-Jul-06	120,000	30,000

amFAR - The Foundation For AIDS Research
 Schedule of Grant Awards and Expense
 Fiscal year 2006
 10/1/2005 - 9/30/2006

13-3163817

Program	Cycled Branch	Grant Id and Name	Location	Period of Performance	Awards	Grant Expense
	40 RGRL	106704 Aaron Diamond AIDS Research Center	New York, NY	01-Jul-06	120,000	30,000
	40 RGRL	106710 University of California, San Francisco	San Francisco, CA	01-Jul-06	120,000	30,000
	40 RGRL	106716 Tulane National Primate Research Center	Covington, LA	01-Jul-06	120,000	30,000
	40 RGRL	106717 Aaron Diamond AIDS Research Center	New York, NY	01-Jul-06	120,000	30,000
	40 RGRL	106719 Tulane National Primate Research Center	Covington, LA	01-Jul-06	120,000	30,000
	40 RGRL	106722 McGill University Health Centre Grant Returns	Montreal, Canada	01-Jul-06	119,827	29,958
					0	(26,973)
					3,372,696	1,648,705

GLOBAL INITIATIVES

33 IGTA	106361	University of New South Wales	Sydney, Australia	01-Apr-03	0	139,899
38 IATA	106651	Grant Medical Foundation - Ruby Hall Clinic	Pune, India	01-Sep-05	0	0
38 OAGN	106655	China Youth Development Foundation	Beijing, China	01-Sep-05	0	0
39 IATA	106694	HIV-MAT: The Netherlands, Australia, Thailand Research Collaboration	Bangkok, Thailand	01-Jan-06	20,000	20,000
39 IATA	106696	National Center for HIV/AIDS, Dermatology	Phnom Penh, Cambodia	01-Mar-06	95,483	95,483
39 IATA	106657	University of New South Wales	Sydney, Australia	01-Mar-06	23,825	23,825
40 IATA	106699	Maryknoll Fathers and Brothers	Maryknoll, NY	01-Apr-06	10,000	10,000
40 IATA	106799	Naz Foundation International, Ltd.	London, England	01-Sep-06	10,000	10,000
40 IATA	106794	Medecis sans Frontieres Belgium, Thailand Mission	Bangkok, Thailand	01-Sep-06	14,901	14,901
40 IATA	106795	University of New South Wales	Sydney, Australia	01-Sep-06	19,404	19,404
40 IATA	106791	University of New South Wales	Sydney, Australia	01-Sep-06	156,297	39,075
40 IGTA	106792	University of New South Wales	Sydney, Australia	01-Jul-06	119,623	26,956
40 IGTA	106793	University of New South Wales Grant Returns	Sydney, Australia	01-Jul-06	157,465	36,366
					0	(23,658)
					626,998	418,291

OUTREACH

35 OAGN	106652	Elton John AIDS Foundation Community Grant	New York, NY	01-Sep-05	0	0
35 OAGN	106656	Monterey Clinical Hurricane Relief Outreach	Houston, TX	01-Sep-05	0	0
40 OAGN	106743	Elton John AIDS Foundation Grant Returns	New York, NY	01-Jul-06	106,952	106,952
					0	0
					106,952	106,952

PREVENTION SCIENCE

35 EGSA	106543	Harlem United Community AIDS Center	New York, NY	01-Apr-04	0	0
49 EASA	106744	Prevention Works! Grant Returns	Los Angeles, CA	01-Aug-06	80,000	80,000
					0	(10,000)
					80,000	70,000

PUBLIC POLICY

35 PGSA	106533	Harm Reduction Program, Beth Israel Medical	New York, NY	01-Apr-04	0	0
38 PAGN	106653	Black AIDS Institute	Los Angeles, CA	01-Sep-05	0	0

amfAR - The Foundation For AIDS Research
 Schedule of Grant Awards and Expense
 Fiscal year 2006
 10/1/2005 - 9/30/2006

13-3163817

Program	Cycle/ Branch	Grant Id and Name	Location	Period of Performance	Awards	Grant Expense
	38 PASA	106611 Beth Israel Medical Center: Baron Edmond de Rothschild Chemical	New York, NY	01-Sep-05 30-Sep-05	0	0
	39 FAGM	106608 Columbia University in the City of New York	New York, NY	01-Mar-06 31-Mar-06	15,000.00	15,000.00
	39 FAMC	106695 University of California, Los Angeles	Los Angeles, CA	01-Jan-06 31-Jan-06	25,000.00	25,000.00
	39 PASA	106697 Harm Reduction Coalition	New York, NY	01-Feb-06 28-Feb-06	10,000.00	10,000.00
	40 PASA	106745 Baron Edmond de Rothschild Chemical Dependency Institute	New York, NY	01-Sep-06 30-Sep-06	70,000.00	70,000.00
		Grant Returns			0	(579)
					<u>120,000</u>	<u>119,421</u>
RESEARCH - GENERAL						
		Reduction of Grant Return Allowance			0	0
					<u>0</u>	<u>0</u>
					<u>3,306,646</u>	<u>2,361,279</u>
Grand Total						

THE FOUNDATION FOR AIDS RESEARCH ("amfAR")
 FY06 FORM 990, KEY EMPLOYEES COMPENSATION SCHEDULE
 For The Period Ended September 30, 2006

Part II - Line 25 - Columns A, B, C

NAME AND ADDRESS	TITLE AND TIME DEVOTED	(A) TOTAL	(B) PROGRAM	(C)		(D) FUNDRAISING
				MANAGEMENT & GENERAL	GENERAL	
Jerome J Radwin c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	CEO Full-Time	\$274,890	\$247,401	\$13,745	\$13,745	\$13,745
		Salary	36,289	2,016	2,016	2,016
		Retirement Plan	11,498	639	639	639
	Total	\$327,986	\$295,187	\$16,399	\$16,399	\$16,399
John F. Logan c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	Asst Secretary, VP, General Counsel Full-Time	\$146,723	\$117,378	\$14,672	\$14,672	\$14,672
		Salary	8,216	1,027	1,027	1,027
		Retirement Plan	5,793	724	724	724
	Total	\$164,234	\$131,387	\$16,423	\$16,423	\$16,423
Scott Newman c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	Asst Treasurer, VP, Finance & Admin Full-Time	\$158,616	\$120,548	\$38,068	\$38,068	\$38,068
		Salary	8,438	2,665	2,665	2,665
		Retirement Plan	6,035	1,906	1,906	1,906
	Total	\$177,660	\$135,022	\$42,638	\$42,638	\$42,638
Deborah Herman c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	Asst Secretary, VP, Public Information Full-Time	\$188,055	\$168,055			
		Salary	11,764	11,764		
		Retirement Plan	10,657	10,657		
	Total	\$190,476	\$190,476			
Judy Auerbach c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	VP, Public Policy Full-Time	\$178,285	\$178,285			
		Salary	12,480	12,480		
		Retirement Plan	7,946	7,946		
	Total	\$198,711	\$198,711			
Bill Melamed c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	VP, Institutional Development Full-Time	\$44,946	\$44,946			\$44,946
		Salary	0	0		
		Retirement Plan	551	551		
	Total	\$45,497	\$45,497			\$45,497

THE FOUNDATION FOR AIDS RESEARCH ("amfAR")
 FY06 FORM 990, KEY EMPLOYEES COMPENSATION SCHEDULE
 For The Period Ended September 30, 2006

TAX ID # 13-3163817

Part II - Line 25 - Columns A,B, C

<u>NAME AND ADDRESS</u>	<u>TITLE AND TIME DEVOTED</u>	<u>(A) TOTAL</u>	<u>(B) PROGRAM</u>	<u>(C) MANAGEMENT & GENERAL</u>	<u>(D) FUNDRAISING</u>
Kevin R Frost c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	VP, Global Initiatives Full-Time	Salary	\$144,332		
		Retirement Plan	10,103		
		Other Benefits	7,245		
		Total	\$161,680		
Rowena Johnston c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	Director, Research Full-Time	Salary	\$107,328		
		Retirement Plan	7,513		
		Other Benefits	7,548		
		Total	\$122,389		
Tor Russell c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	Asst Treasurer, Controller Full-Time	Salary	\$75,454	\$15,091	
		Retirement Plan	5,282	1,056	
		Other Benefits	7,940	1,588	
		Total	\$88,676	\$17,735	
Mervyn F. Silverman, M.D., M.P.H. c/o amfAR 120 Wall Street, 13th Floor New York, NY 10005-3902	Former Director One hour per week	Consultant Fee	\$42,168		
		Salary	\$1,340,797	\$81,575	\$73,363
		Retirement Plan	108,836	99,029	3,043
		Other Benefits	69,845	63,074	1,914
	TOTAL	\$1,519,478	\$1,347,962	\$93,196	\$78,320

The Foundation's mission and programs require a full-time, effective and committed staff to be successful. The public and amfAR's constituents expect amfAR to be managed in an efficient, professional manner by talented and productive professional staff. Therefore, amfAR offers competitive compensation in order to attract and retain the highest level of staff leadership and management. While desiring to be competitive, the Foundation is also committed to the highest standards of stewardship of public funds. Accordingly, in depth labor market analysis, with the aid of external independent compensation consulting firms, is conducted at appropriate intervals.

FORM 990, PART II - OTHER EXPENSES

DESCRIPTION	TOTAL	PROGRAM SERVICES	MANAGEMENT AND GENERAL	FUNDRAISING
PROGRAM TECHNICAL SUPPORT	360,760.	360,760.		
PROFESSIONAL FEES	1,120,319.	929,450.	90,276.	100,593.
PROGRAM MATERIALS	1,221,217.	1,221,217.		
BUSINESS INSURANCE	96,272.	62,076.	16,193.	18,003.
SUBSCRIPTIONS	84,558.	69,252.	6,859.	8,447.
MEMBERSHIPS AND DUES	40,613.	25,736.	677.	14,200.
ADVERTISING & A/V PROD.	59,179.	49,850.	2,258.	7,071.
BAD DEBT EXPENSE	419,642.	270,585.	70,584.	78,473.
MISCELLANEOUS EXPENSE	45,386.	25,303.	4,937.	15,146.
OTHER FEES	233,975.	55,817.	130,117.	48,041.
TOTALS	3,681,921.	3,070,046.	321,901.	289,974.

formerly known as the AMERICAN FOUNDATION FOR AIDS RESEARCH

(A New York Not-for-Profit Corporation)

d.b.a. "amfAR," "AIDS Research Foundation," and

"American Foundation for AIDS Research"

Statement of Program Service Accomplishments

The Foundation for AIDS Research is a national not-for-profit organization incorporated in New York in 1989. amfAR was formed through the unification in 1985 of two not-for-profit organizations, the AIDS Medical Foundation ("AMF"), incorporated in New York in April 1983, and the National AIDS Research Foundation, incorporated in California in August 1985. First based in California, amfAR transferred its legal domicile to New York in 1989, using the initial incorporation documents of AMF, making it AMF's legal successor. amfAR has offices in New York, N.Y., Washington, D.C., and Bangkok, Thailand. On March 7, 2005, the Board of Trustees of the American Foundation for AIDS Research approved a change in legal name to "The Foundation for AIDS Research." On October 18, 2005, the New York State Department of State approved this change. In addition, the Foundation has secured approval for Doing Business As (DBA) the following:

- American Foundation for AIDS Research
- amfAR
- AIDS Research Foundation

The mission of The Foundation for AIDS Research (amfAR) is to prevent HIV infection and the disease and death associated with it and to protect the human rights of all people threatened by the epidemic of HIV/AIDS. The Foundation pursues this mission through:

- research to explore scientific approaches for preventing and treating HIV infection and enhancing the health and survival of people with HIV/AIDS;
- global initiatives to facilitate the development and implementation of effective research, treatment, prevention, and education strategies in developing countries;

- public policy analysis and the advocacy of rational and compassionate policies that promote public health and protect the rights of people threatened by HIV/AIDS;
- education and information programs to build awareness of the continued threat HIV/AIDS poses and to provide up-to-date medical, scientific, and prevention information to people with HIV/AIDS, health-care professionals, and the public.

RESEARCH

amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented grants and fellowships that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential "seed" money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health (NIH). amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research.

Both grants and fellowships are selected through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee (SAC). Guided by its scientific advisors and with the approval of its Board of Trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS.

Research studies make an initial impact on the AIDS field and the broader scientific community when published in scientific journals. Over the past year, 31 scientific publications resulted from amfAR-funded research. These covered current and past targeted areas of research interest such as cellular restriction factors, AIDS vaccine development, novel viral and cellular targets, viral reservoirs and latency, and microbicide research and development.

New Targeted RFPs

In October 2005, amfAR issued a request for proposals (RFP) for new research on HIV prevention. Recent research suggests there are several time points at which interventions could help prevent or modify HIV infection: (1) before transmission takes place; (2) after transmission, but before viral integration; and (3) after integration, but before the generalized spread of infection. amfAR's aim is to promote the development of practical strategies that could be used to inhibit infection at any of these time points.

In March 2006, the Foundation announced six one-year research grants and four two-year fellowships totaling nearly \$1 million for new prevention research. A list of those projects along with brief descriptions can be found at www.amfAR.org.

In December 2005, amfAR convened a think tank in which leading scientists discussed the feasibility of eradicating HIV from the body and the obstacles that stand in the way of achieving that goal. As a result, a second request for proposals was released to the scientific community on January 24, 2006, soliciting proposals on the subject of exploring the potential for HIV eradication.

This RFP also offered to support professional development activities to enhance the careers of young fellows and improve their chances of garnering subsequent funding from the NIH. In June 2006, amfAR announced eight one-year research grants and four two-year fellowships for research on HIV eradication, totaling nearly \$1.5 million; these, too, can be found at www.amfAR.org.

Because of the stigma associated with receptive anal intercourse—the riskiest sexual behavior in terms of acquiring HIV—little research has been conducted on the subject. To address the pressing need for more information, an additional request for proposals was issued in June 2006, soliciting behavioral and biomedical research proposals aimed at preventing rectal transmission of HIV. These awards—6 grants and two fellowships—were announced in January 2007.

Progress in Designing AIDS Vaccines

In the February 2006 issue of *The Journal of Virology*, Drs. Florence Brunel and Rosa Cardoso of the Scripps Research Institute in La Jolla, California, both funded by amfAR,

identified the exact regions of HIV that appear to elicit anti-HIV antibodies capable of neutralizing many different strains of HIV. These broad reactions are critical to vaccine design, because it would be an insurmountable task to design different vaccines to cover every type of AIDS virus circulating in the world.

Microbicides

amfAR grantee Dr. Julian Ma of St. George's Hospital Medical School in London took on an unusual challenge—producing quantities of a microbicide (cyanovirin) sufficient to satisfy worldwide demand. Cyanovirin, a small protein taken from a bacterium normally found in water, latches on to the outer coat of all known AIDS viruses, preventing them from infecting a cell. Utilizing an innovative way of getting the gene that makes cyanovirin into plants, Dr. Ma's group reported in the December 2005 issue of *FASEB Journal* that they had subverted a tobacco plant's normal protein engineering system into making industrial quantities of the microbicide.

Is HIV Weakening?

Dr. Ryan Troyer, of Case Western Reserve University in Cleveland, and colleagues described changes in the fitness of HIV in large populations over time. When they compared blood samples taken from one set of patients in the 1980s with those taken from a different set of patients in the past few years, what they found and published in the October 14 issue of the journal *AIDS* was a hint that HIV might be weakening. This phenomenon is not unusual among infectious diseases, but what is remarkable in this case is that these researchers observed a weakening in only twenty years.

Designer Drugs

Dr. Thomas L. James from the University of California, San Francisco, writing in the journal *Chemistry & Biology*, reported on his amfAR-funded work with a new class of anti-HIV agents. This research targeted neither the two viral enzymes for which FDA-approved drugs now exist (reverse transcriptase and protease), nor integrase, the promising third HIV enzyme target, nor viral fusion and entry. Instead his group sought to target a critical piece of viral genetic information known as TAR RNA. Building on an initial observation that derivatives of anti-depressant drugs, or phenothiazines, bind to TAR RNA, they used chemical and computer-based techniques to design molecules that

best blocked the function of this RNA, forming a chemical "library" of potential drug candidates to explore.

Clinical Research

amfAR's clinical research efforts seek to improve the clinical management of HIV/AIDS and raise standards of care for people with HIV disease. In September 2006, amfAR organized a think tank to address two major problems facing HIV-infected liver transplant recipients: organ rejection and hepatitis C (HCV) infection. The full-day meeting of HIV and transplant immunologists explored the immunologic aspects of organ rejection and HIV/HCV experts discussed post-transplant HCV treatment strategies and outcomes.

GLOBAL INITIATIVES

amfAR's Global Initiatives program utilizes the Foundation's scientific, social science, public policy, and education and information expertise to help health-care workers and AIDS organizations in resource-poor countries develop and implement effective research, treatment, prevention, and education programs.

TREAT Asia

amfAR's TREAT Asia initiative is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific.

TREAT Asia Network Meeting—The sixth annual meeting, held in Siem Reap, Cambodia, July 13-16, brought together more than 90 individuals from 15 countries across Asia, along with representatives from the NIH, the World Health Organization, and PharmAccess Foundation, among others. The network reviewed the progress of its expanding initiatives and laid plans for future growth.

HIV Drug Resistance Project—The spread of drug-resistant HIV represents a growing threat that could undermine the effectiveness of treatment programs across Asia. Most research to date has been confined to the HIV subtypes that are common in the West rather than those that predominate in Asia. In October 2005, TREAT Asia, along with

the PharmAccess Foundation, was awarded 10.2 million Euros (approximately US\$12.5 million) from the Stichting AIDS Fonds to help build capacity for HIV drug resistance surveillance and monitoring in developing countries in Asia and Africa.

Internet Health-Care Training—In December 2005, TREAT Asia launched a 12-week pilot program with HIVeDucation in Pune, India. The program, designed for health-care providers, combines e-learning over the Internet with two live interactive programs as a means of increasing knowledge and skills around HIV/AIDS treatment and care. This pilot project enrolled 25 doctors from across India.

Cambodian Physicians Training—In March 2006, a series of training programs supported by TREAT Asia was launched in Cambodia as part of the country's continuing education campaign for health-care workers involved in HIV treatment and care. Supported in part by the NIH's Office of AIDS Research, the programs includes regional workshops, mentoring programs, and the first national symposium on HIV medicine, held in September.

TREAT Asia HIV Observational Database (TAHOD)—TREAT Asia pioneered the region's first observational database for HIV/AIDS, which now includes anonymous data collected from more than 3,000 patients. The information gathered and analyzed through the database informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. In February 2006, amfAR was awarded a grant of \$3.2 million over five years from the NIH in support of the TREAT Asia observational database. In addition to the 15 sites already participating, two new sites have joined TAHOD: Port Moresby General Hospital (Papua New Guinea) and the College of Medicine, Yonsei University (South Korea).

MSM Regional Coordination Secretariat—In 2006, TREAT Asia signed a contract with Family Health International to serve as the Regional Coordination Secretariat for a new network of HIV programs for men who have sex with men (MSM) in the Greater Mekong Subregion. The Secretariat will initially be funded by the U.S. Agency for International Development and the U.S. Centers for Disease Control and Prevention's Global AIDS Program. The network consists of governmental and nongovernmental organizations working to prevent and treat HIV among MSM in six countries: Cambodia, China

(Yunnan and Guangxi provinces), Laos, Myanmar, Thailand, and Vietnam. The first regional network meeting was held in Bangkok July 31–August 1.

Treatment Education and Training—With support from GlaxoSmithKline's Positive Action, TREAT Asia launched a series of projects aimed at strengthening the community response to HIV/AIDS across the region. These include: (1) community education and treatment literacy programs that are a key component of a pilot treatment and care project among four counties in China; (2) a collaborative effort with the Asia Pacific Network of People Living with AIDS (APN+) to increase community awareness and build capacity on treatment issues in Cambodia and Vietnam; (3) providing HIV/AIDS treatment outreach to the injection-drug-using community in Thailand; and (4) establishing the Asian Community for AIDS Treatment and Advocacy (ACATA) comprised of representatives from TREAT Asia sites/countries with an established need for increased community treatment education.

International AIDS Database—In February, TREAT Asia was selected by the U.S. National Institute of Allergy and Infectious Diseases to join an international collaboration to study global trends in the HIV/AIDS pandemic. Funded by a grant of US\$3.2 million over five years, TREAT Asia will manage the Asia/Pacific section of the International Epidemiologic Databases to Evaluate AIDS. This initiative aims to create a global database large enough to allow detailed study of the spread of HIV infection worldwide and to identify trends in the use and efficacy of HIV treatments in different regions.

International AIDS Conference—At the XVI International AIDS Conference in Toronto, Canada, in August 2006, amfAR and TREAT Asia introduced a special report titled *MSM and HIV/AIDS Risk in Asia: What Is Fueling the Epidemic Among MSM and How Can It Be Stopped?* Widely covered by the media, the report was distributed on CD-ROM to more than 25,000 conference participants. TREAT Asia also sponsored or participated in a variety of activities at the conference, including: a keynote address delivered by ACATA member Frika Iskandar; a workshop on treatment education for low-literacy patients; a symposium on developing health literacy in resource-limited settings; a panel on leadership among people with AIDS; and the presentation of three research papers from TAHOD.

PUBLIC POLICY

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation's Public Policy program is engaged in efforts to secure necessary increases in funding for HIV/AIDS research, including vaccine and microbicide research; implement an evidence-based, national HIV prevention strategy, including repeal of the current ban on federal funding for syringe exchange programs; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS.

Women and HIV

Recognizing the increasingly disproportionate impact of HIV/AIDS on women and girls around the world, amfAR developed the Women's Initiative on Sexual Health and HIV. Key components of the initiative include advancing research on sex and gender and HIV/AIDS, organizing educational symposia and policy briefings to disseminate research findings, and facilitating the formation of the Women and HIV/AIDS Coalition to advocate an evidence-based approach to education for and policies related to women and HIV/AIDS.

As part of the Women's Initiative, in January 2006, amfAR co-sponsored a Congressional briefing to address the underlying factors that make minority women especially vulnerable to HIV and to educate legislators about HIV's devastating impact on women of color. Organized with the Society for Women's Health Research and Women's Policy, Inc., the event was attended by over 200 Congressional staff, members of the press, researchers, and community advocates.

Throughout 2005, amfAR, in collaboration with the Well Project, convened a series of meetings among HIV/AIDS, women's health, and reproductive health organizations. These meetings culminated in the official launch of the Women and HIV/AIDS Coalition (WHAC) on March 8, 2006, as part of National Women and Girls HIV/AIDS Awareness Day.

Harm Reduction and Prevention

An advocate of harm reduction programs to prevent the spread of HIV infection, amfAR funds the only annual national survey of U.S. syringe exchange programs, which is traditionally published in the Centers for Disease Control and Prevention's *Morbidity and Mortality Weekly Report* (MMWR). In 2006, the Foundation also provided \$50,000 to PreventionWorks! to help fund key syringe exchange and harm reduction programs in Washington, DC. Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 15 authorized syringe exchange programs statewide, which currently serve over 116,000 registered participants.

On June 13, amfAR co-sponsored a Congressional briefing entitled *When "Just Say No" Isn't Enough: Stopping HIV Infections among Drug-Using Populations*. This briefing brought together a panel of syringe exchange advocates and public health experts who urged that lifesaving public health measures such as syringe exchange programs be made available for individuals who are unable to quit using drugs.

At the XVI International AIDS Conference in Toronto, Canada, in August, amfAR partnered with the Sexuality Information and Education Council of the United States and Population Action International to form the Caucus for Evidence-Based Prevention, which served as a coordinating and convening body for U.S.-based NGOs to promote evidence-based approaches to HIV prevention.

amfAR also sponsored a symposium at the International AIDS Conference titled *Drug Use, Harm Reduction, and HIV Among Women*. It offered a broad epidemiological overview of HIV among women injection drug users; discussed research findings about the links between drug use and HIV infection among women; assessed interventions that have been developed to address these links; discussed emerging epidemics and innovative harm reduction programs; and highlighted future directions for research, policy, and advocacy.

Prevention for Men Who Have Sex With Men

In June 2006, amfAR's public policy office released an issue brief entitled *HIV Prevention for Men Who Have Sex With Men* (MSM), which examined trends in

HIV/AIDS among MSM, evaluated risk factors, highlighted effective HIV prevention programs, and identified barriers to prevention among MSM populations. amfAR also sponsored a symposium at the International AIDS Conference entitled *HIV Prevention Among Men Who Have Sex With Men*, which examined the epidemiological, sociocultural, behavioural, and biological risk factors that contribute to the new infections among this group.

Scientific Integrity

amfAR continues its leadership among HIV/AIDS and public health organizations on the issue of the politicization of science by certain members of Congress and the current Administration. The Foundation is an active member of the Integrity of Science Working Group (spearheaded by the Union of Concerned Scientists and the Reproductive Health Technologies Project). Under the aegis of the Working Group, amfAR participated in a panel session at the annual American Public Health Association meeting in December 2005 on the politicization of science related to HIV/AIDS.

The Coalition to Protect Research, of which amfAR is a member, has continued to educate members of Congress and their staff about the benefits of sexual health research, which continues to be under attack.

Federal HIV/AIDS Programs

amfAR advocates for reasonable federal funding increases for HIV/AIDS research, prevention, care, and treatment programs. Fiscal 2006 was a particularly tight budget year, and despite amfAR's aggressive opposition to the final Labor/HHS/Education bill, it passed with very low levels of funding for many of the Foundation's priorities. The NIH, for example, received a cut for the first time since 1970.

Advocacy efforts continued in the campaign to allow the District of Columbia to use its own tax dollars to support local syringe exchange programs. This year, amfAR sent a letter to conferees signed by Kenneth Cole, chairman of the board, and Dr. Mathilde Krim, founding chairman, requesting they lift the restriction on D.C.'s expenditures, but, as in years past, the ban passed.

EDUCATION AND INFORMATION

amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues to diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also organizes and hosts community forums for people infected with or affected by HIV/AIDS, publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS.

Continuing Medical Education

amfAR's professional education program seeks to keep health-care providers well informed about the latest advances in HIV treatment, and the prevention and medical management of opportunistic infections, cancers, and other complications of HIV/AIDS. Accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Foundation develops and organizes continuing medical education (CME) courses for physicians and other health-care professionals.

Optimizing Antiretroviral Therapy in the Treatment-Experienced Patient—A series of live CME programs on this subject was held in Philadelphia, Detroit, Kansas City, Miami, Phoenix, and Seattle during June-July 2006, attracting nearly 300 physicians and HIV health-care professionals. The series was supported by an unrestricted educational grant from Tibotec Therapeutics. Topics included: etiology of HIV drug resistance; identifying and assessing drug resistance; adding/switching antiretroviral (ARV) drugs; new ARV agents; ARV toxicities and side effects; and inclusion of the patient in treatment decisions and in discussions of treatment goals. A companion DVD was distributed to those unable to attend the live events.

Think Tanks

Liver Transplant Think Tank—On September 21, amfAR held a think tank to address two major problems facing HIV-infected liver transplant recipients: organ rejection and hepatitis C (HCV) infection. The full-day meeting of HIV and transplant immunologists

explored the immunologic aspects of organ rejection; experts also discussed post-transplant HCV treatment strategies and outcomes.

Print and Electronic Materials and Media Activities

We All Have AIDS Public Awareness Campaign— amfAR was a key partner in the creation and launch of the public service campaign *We All Have AIDS* on December 1, 2005, World AIDS Day. The campaign was spearheaded by amfAR Chairman Kenneth Cole and was produced in strategic partnership with KNOW HIV/AIDS, a joint public education initiative of Viacom, Inc., and the Kaiser Family Foundation. Its aim was to combat the persistent stigma surrounding HIV/AIDS. Featuring HIV/AIDS activists, people with HIV/AIDS, researchers, and celebrities representing various HIV/AIDS organizations around the world, the multimedia campaign gained extensive national and international exposure. The *We All Have AIDS* photograph and message appeared in print domestically and internationally, and on radio stations and 2,000 billboards throughout the U.S.

Special Issue of AIDS Patient Care and STDs—A July 2006 special issue of the publication *AIDS Patient Care and STDs*, edited by amfAR's Senior Scientific Consultant Dr. Jeffrey Laurence, paid tribute to the outstanding accomplishments of amfAR's Founding Chairman, Dr. Mathilde Krim. It included articles by amfAR Chairman Kenneth Cole, AIDS activist Larry Kramer, Dr. Ron Bayer, Dr. Arthur Ammann, Dr. Allan Rosenfield, Dr. Don Des Jarlais, Dr. Carl Wild, Dr. Kenneth Mayer, and Dr. Don Abrams. This special issue was distributed at the 2006 International AIDS Conference in Toronto, Canada.

amfAR produces a range of periodicals in both print and electronic formats, including: *amfAR News*, published twice a year and distributed to 70,000; *The TREAT Asia Report*, published and distributed quarterly to an international audience of 14,000; and a monthly email newsletter distributed to more than 30,000. The Foundation's web site, which receives an average of 100,000 visitors each month, features news, program overviews, and original articles covering science ("Fighting HIV with Genetics"), policy ("When 'Just Say No' Isn't Enough—Stopping HIV Infections Among Drug-Using Populations"), the global epidemic ("Twenty-Five Years of AIDS Marks Grim Milestone,") and amfAR programs and activities.

The Foundation also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts additional public service advertising campaigns that have been instrumental in educating policy makers, health-care professionals, people with HIV/AIDS, and the general public. Educational materials were distributed widely via amfAR and TREAT Asia booths at the International AIDS Conference. A survey of Conference participants was also undertaken to assess needs and inform the development and delivery of innovative new educational programs.

In 2006, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. amfAR staff and board members were quoted widely in the media on the 25th anniversary of the first reported cases of HIV/AIDS in June 2006. On June 13, Kenneth Cole, chairman of the Foundation's board of trustees, was featured on a live webcast sponsored by the Kaiser Family Foundation, which focused on his HIV/AIDS activism and strategies for successful activism. On June 19, amfAR's founding chairman, Dr. Mathilde Krim, appeared on a *New York Times* panel marking the anniversary of the newspaper's first report on the disease. Through its speakers' bureau, the Foundation was able to arrange other speaking engagements that helped educate a wide range of audiences about HIV/AIDS research, treatment, prevention, and policy.

FORM 990, PART IV - INVESTMENTS - SECURITIES

=====

DESCRIPTION -----	BEGINNING BOOK VALUE -----	ENDING BOOK VALUE -----	COST OR FMV -----
MUTUAL FUNDS	6,040,202.	5,086,231.	FMV
U.S. TREASURY FUNDS	1,628,802.	3,077,048.	FMV
CERTIFICATES OF DEPOSIT	709,831.	899,615.	FMV
EQUITIES	72,608.	62,797.	FMV
	-----	-----	
TOTALS	8,451,443.	9,125,691.	
	=====	=====	

THE FOUNDATION FOR AIDS RESEARCH
FORM 990, PART IV - OTHER ASSETS
=====

13-3163817

DESCRIPTION -----	BEGINNING BOOK VALUE -----	ENDING BOOK VALUE -----
SECURITY DEPOSITS	101,751.	98,902.
L/T RETIREMENT INVESTMENT	24,270.	43,037.
TOTALS	----- 126,021. -----	----- 141,939. -----

FORM 990, PART IV - DEFERRED REVENUE
 =====

DESCRIPTION -----	BEGINNING BOOK VALUE -----	ENDING BOOK VALUE -----
DEFERRED SUPPORT	934,100.	997,987.
REFUNDABLE ADVANCES	805.	186.
	-----	-----
TOTALS	934,905.	998,173.
	=====	=====

FORM 990, PART IV - OTHER LIABILITIES

DESCRIPTION -----	BEGINNING BOOK VALUE -----	ENDING BOOK VALUE -----
DEFERRED LEASE EXPENSE	552,503.	528,221.
L/T RETIREMENT INVESTMENT	24,270.	43,037.
TOTALS	----- 576,773. -----	----- 571,258. -----

FORM 990, PART IV-A - OTHER REVENUE ON RETURN BUT NOT ON BOOKS

DESCRIPTION -----	AMOUNT -----
SALE OF FIXED ASSETS	4,126. -----
TOTAL	4,126. =====

FORM 990, PART IV-B - OTHER EXPENSES ON RETURN BUT NOT ON BOOKS
=====

DESCRIPTION -----	AMOUNT -----
SALE OF FIXED ASSETS	4,126.

TOTAL	4,126.
	=====

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-A - CURRENT OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
DAME ELIZABETH TAYLOR 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	FOUNDING INT'L CHAIR 1 HR/WK	NONE	NONE	NONE
MATHILDE KRIM, PHD 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	FOUNDING CHAIRMAN 1 HR/WK	NONE	NONE	NONE
KENNETH COLE 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	CHAIR OF THE BOARD 1 HR/WK	NONE	NONE	NONE
PATRICIA J. MATSON 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	VICE CHAIRMAN 1 HR/WK	NONE	NONE	NONE
JOHN C. SIMONS 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	VICE CHAIRMAN 1 HR/WK	NONE	NONE	NONE
WALLACE SHEFT, C.P.A. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TREASURER 1 HR/WK	NONE	NONE	NONE
WILLIAM D. ZABEL, ESQ.	SECRETARY 1 HR/WK	NONE	NONE	NONE

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-A - CURRENT OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908				
ARLEN H. ANDELSON, ESQ. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
WILLIAM M. APPELBAUM 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
HARRY BELAFONTE 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
ZEV BRAUN 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
JONATHAN S. CANNO 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
DONALD CAPOCCIA 120 WALL STREET 13TH FLOOR	TRUSTEE 1 HR/WK	NONE	NONE	NONE

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-A - CURRENT OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
NEW YORK, NY 10005-3908				
JANE B. EISNER 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
ARNOLD W. KLEIN, M.D. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
MICHAEL J. KLINGENSMITH 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
MICHELE V. MCNEILL, PHARM.D. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
BILL MELAMED (THROUGH 9/06) 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
RICHARD H. METZNER 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-A - CURRENT OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
EDWARD MILSTEIN 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
NATASHA RICHARDSON 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
ALLAN ROSENFELD, M.D. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
ALAN D. SCHWARTZ 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
KEVIN WENDLE 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	TRUSTEE 1 HR/WK	NONE	NONE	NONE
JEROME J. RADWIN 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	C.E.O. 40 HRS/WK	274,890.	53,096.	NONE
JOHN F. LOGAN, J.D., PH.D.	ASST.SEC., V.P. & G.C. 40 HRS/WK	146,723.	17,511.	NONE

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-A - CURRENT OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	V.P. PUBLIC INFO ASST. SEC 40 HRS/WK	168,055.	22,421.	NONE
DEBORAH HERNAN 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	ASST. TREAS, V.P.FIN 40 HRS/WK	158,616.	19,044.	NONE
SCOTT NEWMAN, M.B.A. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	ASST. TREAS & CONT. 40 HRS/WK	75,454.	13,222.	NONE
TOR P. RUSSELL (THROUGH 6/06) 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	V.P. PUBLIC POLICY 40 HRS/WK	178,285.	20,426.	NONE
JUDY AUERBACH (THROUGH 5/06) 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	V.P. INST. DEV. 40 HRS/WK	44,946.	551.	NONE
BILL MELAMED (BEGINNING 5/06) 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	V.P. GLOBAL INIT. 40 HRS/WK	144,332.	17,348.	NONE
KEVIN FROST 120 WALL STREET 13TH FLOOR				

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-A - CURRENT OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
NEW YORK, NY 10005-3908				
ROWENA JOHNSTON 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	DIRECTOR, RESEARCH 40 HRS/WK	107,328.	15,061.	NONE
GRAND TOTALS		1,298,629.	178,680.	NONE

The Foundation's mission and programs require a full-time, effective and committed staff to be successful. The public and amfAR's constituents expect amfAR to be managed in an efficient, professional manner by talented and productive professional staff. Therefore, amfAR offers competitive compensation in order to attract and retain the highest level of staff leadership and management. While desiring to be competitive, the Foundation is also committed to the highest standards of stewardship of public funds. Accordingly, in depth labor market analysis, with the aid of external independent compensation consulting firms, is conducted at appropriate intervals.

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

FORM 990, PART V-B - FORMER OFFICERS, DIRECTORS, AND TRUSTEES

NAME AND ADDRESS	LOANS AND ADVANCES	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCT AND OTHER ALLOWANCES
MERVYN F. SILVERMAN, MD., M.P.H. 120 WALL STREET 13TH FLOOR NEW YORK, NY 10005-3908	NONE	42,168.	NONE	NONE
GRAND TOTALS	NONE	42,168.	NONE	NONE

Mervyn F. Silverman, who left the Board in June of 2005, was retained in a written contract dated April, 2006 as a consultant to research and prepare a comprehensive report relating to the translation and dissemination of HIV/AIDS scientific, policy and global information. The Board was informed of this arrangement. Dr. Silverman was chosen because of his extensive experience and unique knowledge of the AIDS epidemic and of educational initiatives undertaken in response to the epidemic.

FORM 990, PART VI, LINE 90A - STATES

=====

AL, AK, AZ, AR, CA, CO, CT, DC, FL, GA,
HI, IL, IN, IA, KS, KY, ME, MD, MA, MI, MN, MS, MO, NE, NV, NH, NJ, NM,
NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI,

THE FOUNDATION FOR AIDS RESEARCH

13-3163817

SCHEDULE A, PART I - COMPENSATION OF THE FIVE HIGHEST PAID EMPLOYEES

NAME AND ADDRESS	TITLE AND TIME DEVOTED TO POSITION	COMPENSATION	CONTRIBUTIONS TO EMPLOYEE BENEFIT PLANS	EXPENSE ACCOUNT
SUSAN KENNEDY 120 WALL STREET, 13TH FLOOR NEW YORK, NY 10005-3902	DIR. HUMAN RESOURCES 40 HRS/WK	101,952.	21,972.	NONE
ANDREW MCINNES 120 WALL STREET, 13TH FLOOR NEW YORK, NY 10005-3902	DIR. PUBLIC RELATIONS 40 HRS/WK	104,434.	33,796.	NONE
JEFFREY J. SMITH 120 WALL STREET, 13TH FLOOR NEW YORK, NY 10005-3902	PUBLIC & PROF EDUC. 40 HRS/WK	95,595.	27,608.	NONE
SUE DOSTER 120 WALL STREET, 13TH FLOOR NEW YORK, NY 10005-3902	DIR. INFO. 40 HRS/WK	100,588.	21,839.	NONE
BENNAH SERFATY 120 WALL STREET, 13TH FLOOR NEW YORK, NY 10005-3902	DIR. MEDIA REL. 40 HRS/WK	91,710.	32,416.	NONE
TOTAL COMPENSATION		494,279.	137,631.	NONE

The Foundation's mission and programs require a full-time, effective and committed staff to be successful. The public and amfAR's constituents expect amfAR to be managed in an efficient, professional manner by talented and productive professional staff. Therefore, amfAR offers competitive compensation in order to attract and retain the highest level of staff leadership and management. While desiring to be competitive, the Foundation is also committed to the highest standards of stewardship of public funds. Accordingly, in depth labor market analysis, with the aid of external independent compensation consulting firms, is conducted at appropriate intervals.

AS DISCUSSED IN STATEMENT 9:

amfAR
GRANTS PROGRAM
09/30/06

GRANT AND AWARD PROGRAMS AS OF SEPTEMBER 30, 2006:

amfAR grants and fellowships are awarded to qualified researchers in a variety of settings for research in all aspects of HIV and AIDS, with current emphasis on research to (1) understand and ultimately prevent the formation of viral reservoirs that are impervious to anti-HIV therapy; (2) develop chemical or natural substances (known as microbicides) that can be applied vaginally or rectally to prevent the sexual transmission of HIV; (3) increase understanding of mucosal transmission mechanisms and **early events** in HIV transmission and infection; and (4) broaden understanding of natural host restriction factors that inhibit HIV-1 replication and identify targets suitable for drug development aimed at promoting the effects of those factors. In addition, amfAR funds clinical studies in HIV/AIDS, prevention research, research on AIDS-related public policy issues, public outreach and education projects, and efforts to address global issues relevant to slowing the spread of HIV infection.

amfAR currently sponsors:

Basic Research Grants — are awarded for a performance period of one year, and are normally for \$100,000, plus up to 20% for indirect costs. Payments are issued contingent upon the submission of required reports (see below). There were 14 Basic Research Grants awarded in fiscal 2006.

Basic Research Fellowships — are grants that satisfy the direct costs of salaries, fringe benefits and laboratory supplies and are awarded to support post-doctoral physicians and scientists embarking on or redirecting a career in HIV/AIDS research who perform research under the supervision of a senior scientist (sponsor). Fellowships are awarded with periods-of-performance of up to two years for a maximum of \$113,636 direct costs and up to 10% in indirect costs. Payments are issued contingent upon the submission of required reports (see below). There were eight fellowships awarded in fiscal 2006.

Payments for Basic Research Grants and Fellowships — Effective June 2001, the methodology for grant payments was modified as part of a revision (for clarification) of the Foundation's *Policies Governing Research Grants and Fellowships*. The implemented methodology for grant payments is as follows:

Payments for one-year research grants are issued quarterly in arrears. The first payment is for 25% of the total grant amount; all subsequent payments are released **in arrears** upon the receipt of reports of expenditures submitted by the grantees and progress reports as required. Payments for grants with performance periods longer than one year (including fellowships) are issued in four installments: the first, for 25% of the total award amount, is issued in the fourth month of the performance period; all subsequent payments are released upon receipt and approval of reports of expenditures submitted by grantees following the end of each of the last three quarter divisions of the performance

period. For one-year grants, approval of required progress reports by amfAR's Senior Scientific Consultant, and Director, Basic Research, and/or Chair of the Basic Research Committee is necessary before the second and fourth payments are issued. For grants with performance periods longer than one year, the required progress reports must be approved before each of the last three payments is released.

Effective September 2005, progress-reporting requirements for two-year (fellowship) grants were changed to mirror one-year grant requirements.

Travel Awards— These are small travel grants awarded to scientists or professors to travel to other institutions worldwide to participate in special programs or training. The maximum grant is \$5,000. There were no Travel Awards awarded in fiscal 2006.

Clinical Research — These grants are awarded to AIDS clinical researchers for the evaluation of new drugs and treatments. There were no Clinical Research Awards awarded during fiscal 2006.

Global Initiatives Grants and Awards — These grants and awards have performance periods that vary from one year or less to three years and are for amounts that range in amount from 3,000 to \$840,000. Payments are made in lump sum or in installments as described in the notice of award. There were ten Global Awards made during fiscal 2006.

Public Policy Awards — These awards typically have a one-year performance period or less. These awards are paid in lump sum or in installments as described in the notice of award. There were four Public Policy Awards made during fiscal 2006.

Community Outreach Awards — Community Outreach Awards (COA) provide community-based organizations or other institutions support for special training, or other special programs and projects that support HIV/AIDS-related services, prevention, education, or care. Awards vary in amount and are paid in lump sum as per agreement or upon review and acceptance of proposal. There was one Community Outreach Award made during fiscal 2006.

Prevention Science Awards— These awards typically have a one-year performance period or less and are paid in lump sum to support research and related activities and interventions relevant to the preventing the transmission of HIV infection. There was one Prevention Science Award awarded during fiscal 2006.

SCHEDULE A, PART IV-A - OTHER INCOME

DESCRIPTION	2004	2003	2002	2001	TOTAL
MISCELLANEOUS INCOME	1,014.	22,485.	23,291.	260.	47,050.
SUBSCRIPTIONS		11,081.	9,282.	11,740.	32,103.
LIST RENTAL	26,995.	40,660.	47,719.	46,772.	162,146.
TOTALS	28,009.	74,226.	80,292.	58,772.	241,299.

G/L Acct. #	Description	FY06 Opening G/L Balance	YTD Add's/Depr	YTD Disposals & Adjustments	Balance Per G/L	Balance per Fixed Asset Report
2000	Equipment	277,006.32	17,689.62	(814.16)	293,881.78	293,881.78
2005	Accumulated Depreciation	(262,523.92)	(7,151.82)	356.27	(269,319.47)	(269,319.47)
	Equipment Subtotal	14,482.40	10,537.80	(457.89)	24,562.31	24,562.31
2010	Computer Hardware	885,982.61	113,562.14		999,544.75	999,544.75
2015	Accumulated Depreciation	(765,830.13)	(82,905.97)		(848,736.10)	(848,736.10)
	Computer Hardware Subtotal	120,152.48	30,656.17	0.00	150,808.65	150,808.65
2020	Computer Software	354,584.00	100,025.34		454,609.34	454,609.34
2025	Accumulated Depreciation	(273,423.27)	(51,319.69)		(324,742.96)	(324,742.96)
	Computer Software Subtotal	81,160.73	48,705.65	0.00	129,866.38	129,866.38
2030	Furniture & Fixtures	386,182.86	127,205.69		513,388.55	513,388.55
2035	Accumulated Depreciation	(295,947.49)	(31,451.61)		(327,399.10)	(327,399.10)
	Furniture & Fixtures Subtotal	90,235.37	95,754.08	0.00	185,989.45	185,989.45
2040	Leasehold Improvements	545,531.70	223,857.45	(45,590.68)	723,798.47	723,798.47
2045	Accumulated Depreciation	(214,735.31)	(83,948.62)	37,346.77	(260,937.16)	(260,937.16)
	Leasehold Subtotal	330,796.39	139,908.83	(7,843.91)	462,861.31	462,861.31
	Total Fixed Assets	2,449,287.49	562,340.24	(66,404.84)	2,985,222.89	2,985,222.89
	Total Depreciation	(1,812,468.12)	(256,777.71)	38,103.04	(2,031,134.79)	(2,031,134.79)
	Net Fixed Assets	636,827.37	325,562.53	(28,301.80)	954,088.10	954,088.10